Amgen   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Thousand Oaks CA United States (1985)

Organization Overview

First Clinical Trial
1994
NCT00869284
First Marketed Drug
1989
epoetin (Epogen)
First NDA Approval
1991
Filgrastim (neupogen)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Amgen | AMGEN | Amgen Astellas Biopharma K.K. | Amgen Europe B.V | AMGEN INC | Amgen Pharma, Munich | Amgen Research (Munich) GmbH | One Amgen Center Drive | Prof. Kristian Reich | Stemgen